Skip to main content
ENDO 2026 Main banner

Adipose Tissue_Appetite_and Obesity

SY18-01 - Beyond the Gut: Novel Molecular Targets Driving the Future of Obesity Treatment

Saturday, June 13, 2026
4:30 PM - 5:00 PM CT
Location: Room W185ABC
Disclosure(s):
Jaime Almandoz: Abbvie: Consultant (); Amgen: Consultant (); Boehringer Ingelheim: Advisory Board (), Consultant (); Eli Lilly & Company: Advisory Board (), Consultant (); Haleon: Advisory Board (), Consultant (); Kailera: Advisory Board (), Consultant (); Metsera: Advisory Board (), Consultant (); Novo Nordisk: Advisory Board (), Consultant (); Rhythm Pharmaceuticals: Advisory Board (), Consultant (); RIvus: Consultant ()
Recent advances in obesity pharmacotherapy are transforming metabolic care through increasingly potent and diverse mechanisms of action. This session will explore next-generation injectable incretin-based agents, including dual and triple receptor agonists; oral and nonpeptide anti-obesity medications designed to improve accessibility, adherence, and long-term weight maintenance; and emerging pathways beyond gut hormones that may redefine how obesity and metabolic diseases are treated. Speakers will integrate preclinical and clinical insights to highlight innovation in drug design, efficacy, and durability—offering a forward-looking view of the evolving therapeutic landscape for obesity.

Learning Objectives:

  • Summarize the mechanisms and clinical outcomes of dual and triple incretin receptor agonists under development for obesity and metabolic disease.
  • Evaluate the potential of oral and nonpeptide therapies to improve patient adherence, access, and treatment durability.
  • Identify novel non-incretin molecular targets and pathways that may expand future therapeutic options for obesity management.